Imagine growing the active ingredients for medicine in a high-tech indoor garden instead of relying on rare trees in distant forests. This technology uses a special automated tank that feeds plant cells just enough liquid to grow them quickly and cleanly. It turns a slow, nature-dependent process into a precise factory-like system.
Pharmaceutical companies rely on slow-growing trees in Chile for critical vaccine ingredients, leading to fragile supply chains and high costs. Current production is resource-intensive and lacks the scalability to meet global demand.
A 40-L modular automated temporary-immersion bioreactor (AlkaBurst 2.0) and a complete bioproduction workflow for QS-21, including AI-assisted robotic cutting for micropropagation.
If you are a vaccine manufacturer dealing with fragile supply chains for QS-21 adjuvants from Chilean trees — this project developed a plant-cell-culture biorefinery that provides a local, standardized production of safe APIs.
If you are a CDMO dealing with high carbon footprints and resource-intensive crops — this project developed the AlkaBurst 2.0 bioreactor that saves 95% electricity and 98% water.
If you are a veterinary vaccine producer dealing with high costs of plant-derived compounds — this project developed a scalable immersion bioreactor that reduces production time by 75%.
The automated process is designed to save 75% of time, 80% of space, 95% of electricity, and 98% of water compared to traditional methods.
Yes, the project validated 40-L modular bioreactors that allow for seamless scalability through parallel operation.
The technology is based on a proprietary and patented automated bioreactor platform called AlkaBurst 2.0.
Analytical comparisons confirmed that the produced QS-21 and saponin fractions are equivalent to pharmaceutical-grade reference materials.
Based on the objective, the company expects to generate 125M in revenue by 2028.
The project is led by a single French SME, Alkion BioInnovations, representing a 100% industry ratio. This lean structure suggests a fast-to-market approach focused on commercialization rather than academic research, utilizing external partnerships for specific needs like AI-assisted robotics.
Contact Alkion BioInnovations in France
Contact us to explore licensing or partnership opportunities with Alkion BioInnovations.
